Home/Pipeline/Folate Receptor-Targeted PCC

Folate Receptor-Targeted PCC

Ovarian Cancer

PreclinicalActive

Key Facts

Indication

Ovarian Cancer

Phase

Preclinical

Status

Active

Company

Indi Molecular

About Indi Molecular

Indi Molecular is a private, preclinical-stage biotech leveraging its proprietary Protein Catalyzed Capture (PCC) platform to create synthetic peptide therapeutics with antibody-like binding properties. Founded in 2012 as a spinout from Integrated Diagnostics, the company has raised a $1.5M seed round and an $11.5M Series A to advance its platform and two lead oncology programs. Its approach aims to combine the high specificity of biologics with the favorable pharmacokinetics and manufacturability of small molecules.

View full company profile

Therapeutic Areas

Oncology

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active